Alterity Therapeutics Raises A$20.0 million in Strategic Placement
MWN-AI** Summary
Alterity Therapeutics, a biotechnology company focused on developing treatments for neurodegenerative diseases, has announced a successful capital raising of A$20 million through a strategic placement of fully paid ordinary shares. This placement attracted binding commitments from institutional investors both in Australia and internationally. David Stamler, CEO of Alterity, expressed gratitude for the strong support from the investment community, particularly following the promising results from their Phase 2 clinical trial for ATH434, targeting Multiple System Atrophy (MSA), a severe Parkinsonian disorder.
The placement was priced at A$0.012 per share, reflecting a 7.7% discount from the last closing price prior to the trading halt. Important to note, no options were issued as part of this transaction, ensuring a straightforward capital increase. The funds raised will bolster Alterity's balance sheet and enable the company to advance its clinical and regulatory efforts with the US FDA, as well as fund essential non-clinical studies and manufacturing activities.
Alterity has recently reported positive topline results from its Phase 2 trials (ATH434-201 and ATH434-202), demonstrating both efficacy and safety of ATH434. The company plans to engage with the FDA to outline the path forward for the drug's development.
With an intention to foster growth and enhance its institutional register, Alterity aims to position itself strategically for potential partnerships. The announcement solidifies Alterity's commitment to addressing the challenges of neurodegenerative diseases, with ATH434 emerging as a promising candidate for future therapeutic development. For more details, investors and interested parties can refer to the company's website.
MWN-AI** Analysis
Alterity Therapeutics' recent announcement of raising A$20 million through a strategic placement of shares signals a strong moment for the biotechnology company, particularly in light of its ongoing development of ATH434, a promising candidate for treating neurodegenerative diseases like Multiple System Atrophy (MSA). The successful placement, with new shares priced at A$0.012 each—representing a modest discount of 7.7%—demonstrates robust investor interest, especially after the favorable results from recent Phase 2 trials.
The additional funding will allow Alterity to bolster its clinical and regulatory strategies as it seeks potential FDA approval and facilitates further non-clinical studies and manufacturing processes. Given that their Phase 2 clinical trial results have shown clinically meaningful efficacy, the prospects for future growth appear favorable.
From a market perspective, investors might find this an opportune moment to assess Alterity's long-term potential. Participation in this placement reflects confidence from institutional investors, which may act as a vote of confidence for retail investors. However, it’s critical to consider the inherent risks associated with biotech investments. The path to regulatory approval is fraught with uncertainties, and while the current data looks promising, it is essential to remain cautious.
Investors should closely monitor the company's financial health post-placement and its capacity to execute on the outlined strategies. Potential partnerships could also augment its growth trajectory. Looking ahead, if Alterity continues to report positive developments and progress towards FDA engagement, the sentiment around its stock could shift positively, warranting a closer examination for potential buy positions. Overall, while there are still risks involved, Alterity's recent advancements and strategic moves could position it favorably in the market.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MELBOURNE, Australia and SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received binding commitments for a capital raising of A$20.0 million (the “Placement”) of fully paid ordinary shares (“New Shares”) to International and Australian professional investors.
"We are thankful for the continued interest from the investment community following the robust efficacy we demonstrated in our Phase 2 clinical trial in Multiple System Atrophy. We look forward to an exciting twelve months ahead as we actively pursue the path to approval,” said, David Stamler, M.D., Chief Executive Officer of Alterity. “We elected to execute this placement due to inbound interest from a high-quality international healthcare-focused fund that anchored the transaction. Based on the promising outlook for the company, we raised these funds at a modest discount with no options. The additional funding allows us to continue advancing our clinical and regulatory strategy for ATH434 with the US FDA and other agencies, while at the same time it strengthens our institutional register and balance sheet to best position the company for pursuing strategic partnerships.”
MST Financial Services Pty Ltd (MST) acted as sole manager of the offering.
Placement details
The Placement was conducted at A$0.012 per share, representing a discount of 7.7% to the last ASX closing price prior to the trading halt and a 7.3% discount to the 10-day volume weighted average price (vwap). There were no options issued as part of this transaction. The new shares to be issued will rank equally with existing ATH fully paid ordinary shares. Further details are set out in the Appendix 3B released to ASX at or about the same time as this announcement.
Use of Proceeds
The use of proceeds from this financing will provide Alterity a strong balance sheet to fund the necessary non-clinical studies, chemical manufacturing and controls (CMC) activities, clinical and regulatory activities for future development of ATH434 in MSA, and general working capital.
During 2025, Alterity has released positive topline results from its ATH434-201 and ATH434-202 Phase 2 clinical trials of ATH434. The data have demonstrated a clinically meaningful benefit and a favorable safety profile. Based on the strength of these Phase 2 data, the company plans to engage with the FDA to discuss the path forward for future development of ATH434.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is initially focused on developing disease modifying therapies in Parkinson’s disease and related disorders. Alterity has demonstrated clinically meaningful efficacy for its lead asset, ATH434, in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with Multiple System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder. ATH434 recently reported positive data in its open label Phase 2 clinical trial in advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com .
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Ana Luiza Harrop
we-aualteritytherapeutics@we-worldwide.com
+61 452 510 255
U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
FAQ**
How does Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) plan to utilize the A$20 million raised in their recent placement to advance their ATH434 product in the neurodegenerative treatment market in Melbourne, Australia?
In what ways could the promising results of Alterity Therapeutics Limited ATHE's Phase 2 clinical trials impact the biotech landscape in San Francisco, California, and foster partnerships with US investors?
Given the ongoing developments of Alterity Therapeutics Limited ATHE, what are the potential challenges the company may face in obtaining FDA approval for ATH4while expanding its operations in both Melbourne and San Francisco?
How is Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) positioning itself to engage with the investment community as it progresses with non-clinical studies and regulatory activities in its Melbourne headquarters and San Francisco offices?
**MWN-AI FAQ is based on asking OpenAI questions about Alterity Therapeutics Limited (NASDAQ: ATHE).
NASDAQ: ATHE
ATHE Trading
4.51% G/L:
$3.5639 Last:
2,120 Volume:
$3.35 Open:
